We work Hard to get you posted with latest updates

http://We%20work%20Hard%20to%20get%20you%20posted%20with%20latest%20updates

Spend time learning about the different aspects of that topic from experts in the field.

AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy

Unwrap our new Directory

http://Unwrap%20our%20new%20Directory

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

BEHOLD-1

Advertisement

cGxPJobs Banner

GSK Reports Strong ADC Data in Ovarian Cancer Study

London, United Kingdom | April 13, 2026 GSK plc has announced positive clinical data from its Phase 1 BEHOLD-1...

By cGxPwire Editor
April 14, 2026

Read More

Advertisement

cGxPJobs

Recent Posts

01

Bio-Pharma

Whitehawk Therapeutics’ PTK7 Data Support ADC Development
September 15, 2026
02

Veterinary

Telomir Advances Telomir-Zn in Human and Canine Osteosarcoma
September 15, 2026
03

Pharma

Bright Path Labs Receives FDA AMT Designation for Medicines
September 15, 2026
04

Bio-Pharma

Armata’s AP-SA02 Receives FDA Breakthrough Designation
September 15, 2026
05

.Tech

Evaxion Expands AI-Immunology Platform Into Autoimmune Disease
September 15, 2026

Advertisement

Copyright © 2026 cGxP.wire | Made by 3styler

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

Start typing and press Enter to search

Loading Comments...

Write a Comment...

Email (Required)

Name (Required)

Website